2024
- Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide. Molecular Cancer, 23(1), 38.
- Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study. Molecular Cancer, 23(1), 37.
- Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study. Biomarker Research, 12(1), 3.
- TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 30(4), 779-785.
2023
- Upregulation of Indoleamine 2, 3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer. Clinical Cancer Research, 29(23), 4883-4893.
- Standardized pathology screening of mature tertiary lymphoid structures in cancers. Laboratory Investigation, 103(5), 100063.
2022
- Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nature medicine, 28(6), 1199-1206.
- Indoleamine 2, 3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. Immunity, 55(6), 1032-1050.
- Targeting tryptophan catabolism in cancer immunotherapy era: challenges and perspectives. Frontiers in immunology, 13, 807271.
- Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. European Journal of Cancer, 162, 161-169.
- Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma. Journal of Hematology & Oncology, 15(1), 149.
- Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. Journal for ImmunoTherapy of Cancer, 10(5).
- Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study. Clinical Cancer Research, 28(9), 1765-1772.
- Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study. Journal of Hematology & Oncology, 15(1), 157.
- Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer. Experimental Hematology & Oncology, 11(1), 104.
- Prophylactic and therapeutic effect of kynurenine for experimental autoimmune encephalomyelitis (EAE) disease. International Journal of Tryptophan Research, 15, 11786469221118657.
- Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Ann Oncol. 33(9):909-915.
- Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. Ann Oncol. 33(10):1041-1051. doi: 10.1016/j.annonc.2022.07.001. Epub 2022 Jul 16. PMID: 35850444.
2021-2018
- Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol., 32(11):1381-1390.
- Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer, 2(8), 794-802.
- Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial. Clinical Cancer Research, 27(8), 2139-2147.
- CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. iScience, 24(11).
- CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism. iScience. 24(12)
- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. The lancet oncology, 21(3), 446-455.
- IDO targeting in sarcoma: biological and clinical implications. Frontiers in Immunology, 11, 274.
- Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome. Biomarker Research, 8(1), 26.
- Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA oncology, 4(1), 93-97.
- Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nature communications, 9(1), 4775.
Get our posters in PDF !
ASCO 2023 TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer
AACR 2023 Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures
AACR 2023 Profiling of immune cell components and soluble factors in ovarian cancer ascites highlights impaired immune environment
AACR 2023 Indoleamine 2,3-dioxygenase 1 is expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1/PDL1 inhibitors
ASCO 2022 Identification of super-exhausted T cells: a novel population predictive of response to immunotherapy
AACR 2022 Low plasma Arginine level is associated with resistance to immune checkpoint inhibitors in patients with advanced cancer
AACR 2022 High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas
AACR 2022 Ovarian cancer ascites display altered immune environment featured by enhanced soluble factors and suppressive cellular context
AACR 2022 Development and characterization of a novel anti-PD1 resistant sarcoma mouse model